Up a level |
Number of items: 1.
Sacco, Joseph J, Jackson, Richard, Corrie, Pippa, Danson, Sarah, Jeffry Evans, TR, Ochsenreither, Sebastian, Kumar, Satish, Goodman, Andrew, Larkin, James, Karydis, Ioannis et al (show 11 more authors)
(2024)
A three-arm randomised Phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma.
European Journal of Cancer.
p. 114009.